{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-073909","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.932775+00:00","generated_at":"2026-05-17T15:18:51.325050+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Raphael Pharmaceutical ready to launch RaphaWell RA supplement in US after clinical trial","bullets":["RaphaWell is a 100% natural, plant-based dietary supplement for rheumatoid arthritis symptom management.","Completed proof-of-concept clinical trial under IRB approval; pain levels reduced from 75% negative to 50% at week 8.","Morning stiffness improved from 75% participants at baseline to 41.67% at week 8.","Company intends to engage a US manufacturer to scale production; product to be sold as standalone supplement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-073909","json":"https://secwatch.observer/filing/0001213900-25-073909.json","markdown":"https://secwatch.observer/filing/0001213900-25-073909.md","text":"https://secwatch.observer/filing/0001213900-25-073909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390025073909/0001213900-25-073909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390025073909/ea0252574-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:18:51.325050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}